|1.||Lin, Thomas S: 2 articles (12/2009 - 03/2004)|
|2.||Byrd, John C: 2 articles (12/2009 - 03/2004)|
|3.||Valerius, Thomas: 2 articles (10/2006 - 09/2002)|
|4.||Repp, Roland: 2 articles (10/2006 - 09/2002)|
|5.||Stockmeyer, Bernhard: 2 articles (10/2006 - 09/2002)|
|6.||Gramatzki, Martin: 2 articles (10/2006 - 09/2002)|
|7.||Dalton, James T: 1 article (12/2009)|
|8.||Lucas, Margaret S: 1 article (12/2009)|
|9.||Porcu, Pierluigi: 1 article (12/2009)|
|10.||Guster, Sara K: 1 article (12/2009)|
09/01/2002 - "Furthermore, Hu1D10 was highly effective in inducing apoptosis in primary lymphoma cells from B chronic lymphocytic leukaemia patients. "
12/01/2009 - "Given the toxicity and lack of efficacy in this and other trials in lymphoma and solid tumors, further development of apolizumab was discontinued."
10/01/2006 - "In pre-clinical studies, we previously reported that granulocyte colony-stimulating factor (G-CSF) treatment significantly enhanced lymphoma cell killing by HLA class II antibodies, including apolizumab. "
09/01/2002 - "Humanized 1D10 (Hu1D10; Remitogen) is among the antibodies that are currently under evaluation in phase II clinical trials in lymphoma patients. "
|3.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
03/01/2004 - "We demonstrate that Hu1D10 induces caspase-independent apoptosis following secondary cross-linking in primary chronic lymphocytic leukemia (CLL) cells. "
03/01/2004 - "Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells."
12/01/2009 - "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia."
12/01/2009 - "Apolizumab (Hu1D10), a humanized monoclonal anti- Human leukocyte antigen -DR beta-chain antibody, mediates apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro. "
|4.||Non-Hodgkin Lymphoma (Lymphosarcoma)
10/01/2006 - "In this trial, we treated six patients with relapsed or refractory 1D10-positive non-Hodgkin's lymphoma with filgrastim and variable doses of apolizumab ranging from 0.15 to 1.5 mg/m2. "
02/01/2002 - "Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)."
10/01/2006 - "A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study."
|5.||Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
12/01/2001 - "Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma."
10/01/2006 - "Interestingly, two patients with follicular lymphoma who received intensified apolizumab treatment on a three times weekly schedule experienced prolonged stabilization of their disease for 12 and more than 36 months. "
10/01/2006 - "Apolizumab is a humanized monoclonal antibody against a polymorphic epitope on HLA DRbeta that demonstrated evidence for therapeutic activity in follicular lymphoma patients. "
|4.||HLA-DR Antigens (HLA-DR)
|6.||Granulocyte Colony-Stimulating Factor (G-CSF)
|7.||hLL2 agent (epratuzumab)